文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

UGT1A1 6/28 多态性可预测中国结直肠癌患者伊立替康引起的严重中性粒细胞减少而非腹泻。

UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.

机构信息

Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University, Cancer Hospital & Institute, No. 52, Fucheng Road, Haidian District, Beijing 100142, China.

出版信息

Med Oncol. 2013;30(3):604. doi: 10.1007/s12032-013-0604-x. Epub 2013 May 18.


DOI:10.1007/s12032-013-0604-x
PMID:23686699
Abstract

The aim of this study was to investigate the associations between UDP-glucuronosyltransferase (UGT) 1A1 polymorphisms and irinotecan-induced toxicities in Chinese advanced colorectal cancer patients. The genotypes of UGT1A1 6 and UGT1A1 28 were analyzed by PCR amplification and Sanger sequencing in 276 advanced colorectal cancer patients receiving irinotecan-containing chemotherapy. The influences of UGT1A1 6/28 polymorphisms on severe diarrhea and neutropenia were analyzed. The overall incidence of UGT1A1 6 and UGT1A1 28 variants was 35.5 % (GA: 28.6 %; AA: 6.9 %) and 21.0 % (TA6/TA7: 19.9 %; TA7/TA7: 1.1 %) in our cohort, respectively. A total of 16 patients (5.8 %, 16/276) had severe diarrhea and 56 patients (20.3 %, 56/276) had severe neutropenia. Neither UGT1A1 6 nor UGT1A1 28 variants were associated with severe diarrhea; however, either UGT1A1 6 (P = 0.001) or UGT1A1 28 (P = 0.029) variants were significantly associated with severe neutropenia. No differences were found between severe toxicities and clinical response in this study. Compared to western countries, Chinese patients had a distinct frequency of UGT1A1 6 or UGT1A1 28 genotypes. Both UGT1A1 6 and UGT1A1 28 variants were closely associated with irinotecan-induced severe neutropenia, but not diarrhea.

摘要

本研究旨在探讨 UDP-葡萄糖醛酸转移酶(UGT)1A1 多态性与中国晚期结直肠癌患者伊立替康诱导毒性的关系。采用聚合酶链反应扩增和 Sanger 测序法对 276 例接受含伊立替康化疗的晚期结直肠癌患者的 UGT1A1 6 和 UGT1A1 28 基因型进行分析。分析 UGT1A1 6/28 多态性对严重腹泻和中性粒细胞减少症的影响。在本队列中,UGT1A1 6 和 UGT1A1 28 变异体的总发生率分别为 35.5%(GA:28.6%;AA:6.9%)和 21.0%(TA6/TA7:19.9%;TA7/TA7:1.1%)。共有 16 例患者(5.8%,16/276)发生严重腹泻,56 例患者(20.3%,56/276)发生严重中性粒细胞减少症。UGT1A1 6 或 UGT1A1 28 变异体均与严重腹泻无关;然而,UGT1A1 6(P=0.001)或 UGT1A1 28(P=0.029)变异体与严重中性粒细胞减少症显著相关。在本研究中,严重毒性与临床反应之间无差异。与西方国家相比,中国患者 UGT1A1 6 或 UGT1A1 28 基因型的频率明显不同。UGT1A1 6 和 UGT1A1 28 变异体均与伊立替康诱导的严重中性粒细胞减少症密切相关,但与腹泻无关。

相似文献

[1]
UGT1A1 6/28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients.

Med Oncol. 2013-5-18

[2]
Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients.

Med Oncol. 2013-6-20

[3]
[Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events].

Zhonghua Zhong Liu Za Zhi. 2018-8-23

[4]
UGT1A1 Gene Polymorphism Predicts Irinotecan-Induced Severe Neutropenia and Diarrhea in Chinese Cancer Patients.

Clin Lab. 2017-9-1

[5]
Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients.

Drug Metab Pharmacokinet. 2016-2

[6]
Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens.

Drug Des Devel Ther. 2015-7-17

[7]
Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.

BMC Cancer. 2017-6-20

[8]
UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.

Cancer. 2008-5-1

[9]
UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis.

Cancer Chemother Pharmacol. 2017-7

[10]
UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.

World J Gastroenterol. 2012-12-7

引用本文的文献

[1]
The role of UGT1A1 polymorphism in the management of colorectal cancer.

Oncol Rev. 2025-5-13

[2]
Gene Mutational Clusters in the Tumors of Colorectal Cancer Patients With a Family History of Cancer.

Front Oncol. 2022-6-24

[3]
Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan-induced toxicity in Asian cancer patients: Meta-analysis.

Clin Transl Sci. 2022-7

[4]
Allele Test Not Only Minimizes the Toxicity But Also Maximizes the Therapeutic Effect of Irinotecan in the Treatment of Colorectal Cancer: A Narrative Review.

Front Oncol. 2022-3-9

[5]
Association of UGT1A1*6 polymorphism with irinotecan-based chemotherapy reaction in colorectal cancer patients: a systematic review and a meta-analysis.

Biosci Rep. 2020-10-30

[6]
Efficacy and safety of Shengjiang Xiexin decoction in prophylaxis of chemotherapy-related diarrhea in small cell lung cancer patients: study protocol for a multicenter randomized controlled trial.

Trials. 2020-5-1

[7]
Role of Genetic Variations in the Hepatic Handling of Drugs.

Int J Mol Sci. 2020-4-20

[8]
Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.

BMC Gastroenterol. 2020-4-7

[9]
Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX.

Cancer Sci. 2018-12-12

[10]
Banxia Xiexin Decoction Is Effective to Prevent and Control Irinotecan-Induced Delayed Diarrhea in Recurrent Small Cell Lung Cancer.

Integr Cancer Ther. 2018-12

本文引用的文献

[1]
Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer.

Cancer Chemother Pharmacol. 2013-3-31

[2]
Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.

Cancer Sci. 2011-8-12

[3]
A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer.

Br J Cancer. 2011-6-7

[4]
Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms.

Jpn J Clin Oncol. 2011-2-7

[5]
Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.

Cancer. 2011-2-1

[6]
UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.

Cancer Chemother Pharmacol. 2010-10-19

[7]
Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results.

Ann Oncol. 2010-9-22

[8]
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.

Br J Cancer. 2010-7-13

[9]
Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.

Pharmacogenomics J. 2010-2-23

[10]
Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study.

Int J Gynecol Cancer. 2010-2

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索